MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

Multiple Sclerosis

Volumn 22, Issue 13, 2016, Pages 1719-1731

  Tourbah, Ayman ^a   Lebrun Frenay, Christine ^b   Edan, Gilles ^c   Clanet, Michel ^d   Papeix, Caroline ^e   Vukusic, Sandra ^f   De Sèze, Jerome ^g   Debouverie, Marc ^h   Gout, Olivier ⁱ   Clavelou, Pierre ^j   Defer, Gilles ^k   Laplaud, David Axel ^l   Moreau, Thibault ^m   Labauge, Pierre ⁿ   Brochet, Bruno ^o   Sedel, Frédéric ^p   Pelletier, Jean ^q  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f HOSPICES CIVILS DE LYON   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^j UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^k CAEN UNIVERSITY HOSPITAL   (France)

^l NANTES UNIVERSITY HOSPITAL   (France)

^m DIJON UNIVERSITY HOSPITAL   (France)

ⁿ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^o BORDEAUX UNIVERSITY HOSPITAL   (France)

^p MedDAY Pharmaceuticals   (France)

^q University of Aix Marseille   (France)

more..

Author keywords

clinical trial; disability progression; high dose biotin; MD1003; Multiple sclerosis; primary progressive multiple sclerosis; secondary progressive multiple sclerosis

Indexed keywords

BIOTIN DERIVATIVE; MD 1003; PLACEBO; UNCLASSIFIED DRUG; BIOTIN; VITAMIN B COMPLEX;

ADULT; AGED; ARTICLE; BACKACHE; BRONCHITIS; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FALLING; FEMALE; FOLLOW UP; GASTROENTERITIS; HEADACHE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MUCOCUTANEOUS RASH; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; OROPHARYNX PAIN; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; SPASTICITY; TREATMENT OUTCOME; URINARY TRACT INFECTION; DISEASE EXACERBATION; MIDDLE AGED; OUTCOME ASSESSMENT;

ADULT; BIOTIN; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; OUTCOME ASSESSMENT (HEALTH CARE); VITAMIN B COMPLEX;

EID: 84994618244     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458516667568     Document Type: Article

References (25)

1. Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology 2014; 83: 1022-1024.
2. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83: 278-286.
3. Lublin FD,. New multiple sclerosis phenotypic classification. Eur Neurol 2014; 72: 1-5.
4. Levin MC, Douglas JN, Meyers L, et al. Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms. Degener Neurol Neuromuscul Dis 2014; 4: 49-63.
5. Stys PK, Zamponi GW, van MJ, et al. Will the real multiple sclerosis please stand up? Nat Rev Neurosci 2012; 13: 507-514.
6. Trapp BD, Stys PK,. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8: 280-291.
7. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471.
8. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-2025.
9. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.
10. Wingerchuk DM, Carter JL,. Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014; 89: 225-240.
11. Sedel F, Papeix C, Bellanger A, et al. High doses of biotin in chronic progressive multiple sclerosis: A pilot study. Mult Scler Relat Disord 2015; 4: 159-169.
12. Sedel F, Bernard D, Mock DM, et al. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology. Epub ahead of print 5 2015, DOI: 10.1016/j.neuropharm.2015.08.028.
13. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
14. Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75: 706-710.
15. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet 2014; 383: 2213-2221.
16. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-687.
17. Freedman MS, Bar-Or A, Oger J, et al. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011; 77: 1551-1560.
18. Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9: 681-688.
19. Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology 2004; 63: 1788-1795.
20. Rice GP, Filippi M, Comi G, et al. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54: 1145-1155.
21. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24.
22. Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: Randomised placebo-controlled trial. Lancet 2004; 364: 1149-1156.
23. Wijeratne NG, Doery JC, Lu ZX,. Positive and negative interference in immunoassays following biotin ingestion: A pharmacokinetic study. Pathology 2012; 44: 674-675.
24. Hobart J, Blight AR, Goodman A, et al. Timed 25-foot walk: Direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology 2013; 80: 1509-1517.
25. Manouchehrinia A, Tanasescu R, Tench CR, et al. Mortality in multiple sclerosis: Meta-analysis of standardised mortality ratios. J Neurol Neurosurg Psychiatry 2015; 87: 324-331.